Patents by Inventor John Mascola
John Mascola has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10562960Abstract: Antibodies and antigen binding fragments that specifically bind to gp120 and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.Type: GrantFiled: March 18, 2016Date of Patent: February 18, 2020Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Mark Connors, Jinghe Huang, Byong Ha Kang, John Mascola, Elise Ishida, Tongqing Zhou, Peter Kwong, Anqi Zheng
-
Publication number: 20200048311Abstract: Embodiments of a recombinant human Parainfluenza Virus (hPIV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the hPIV F ectodomain trimer and methods of producing the hPIV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or inhibiting a hPIV infection in a subject by administering a effective amount of the recombinant hPIV F ectodomain trimer to the subject.Type: ApplicationFiled: October 25, 2017Publication date: February 13, 2020Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Services, Institute for Research in BiomedicineInventors: Baoshan Zhang, Guillaume Stewart-Jones, Tongqing Zhou, John Mascola, Kai Xu, Yongping Yang, Paul Thomas, Gwo-Yu Chuang, Li Ou, Peter Kwong, Yaroslav Tsybovsky, Wing-Pui Kong, Aliaksandr Druz, Davide Corti, Antonio Lanzavecchia
-
Patent number: 10519222Abstract: The present invention relates anti-HIV therapies and prophylaxis. Specifically, the invention relates to broadly neutralizing antibodies against HIV-1, nucleic acids encoding these antibodies, vectors comprising the nucleic acids and cells and pharmaceutical compositions Comprising said vectors and/or antibodies. The present invention also relates to use of the antibodies and/or vectors for the treatment and/or prevention of HIV-1 infection in a subject. Furthermore, the invention also relates to a kit containing the antibodies of the invention.Type: GrantFiled: February 27, 2015Date of Patent: December 31, 2019Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, CENTRE FOR THE AIDS PROGRAMME OF RESEARCH IN SOUTH AFRICA, UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG, NATIONAL HEALTH LABORATORY SERVICEInventors: Chaim Aryeh Schramm, Jason Gorman, John Mascola, Lawrence Stewart Shapiro, Lynn Morris, Nicole Amy Doria-Rose, Penelope Linda Moore, Peter Dak Pin Kwong, Salim Safurdeen Abdool Karim
-
Publication number: 20190389915Abstract: HIV-1 Env ectodomain trimers stabilized in a prefusion mature closed conformation and methods of their use and production are disclosed. In several embodiments, the HIV-1 Env ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject. In additional embodiments, the therapeutically effective amount of the HIV-1 Env ectodomain trimers can be administered to a subject in a method of treating or preventing HIV-1 infection.Type: ApplicationFiled: August 30, 2019Publication date: December 26, 2019Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Peter Kwong, Marie Pancera, Tongqing Zhou, Ivelin Georgiev, Michael Gordon Joyce, Priyamvada Acharya, Jason Gorman, Yongping Yang, Guillaume Stewart-Jones, Rita Chen, Gwo-Yu Chuang, John Mascola, Baoshan Zhang, Cheng Cheng, Mallika Sastry
-
Publication number: 20190345205Abstract: Compounds useful as components of immunogenic compositions for the induction of an immunogenic response in a subject against viral infection, methods for their use in treatment, and processes for their manufacture are provided herein. The compounds comprise a nucleic acid construct comprising a sequence which encodes a Zika virus antigen.Type: ApplicationFiled: November 15, 2017Publication date: November 14, 2019Applicants: GLAXOSMITHKLINE BIOLOGICALS, S.A., The United States of America, as Represented by the Department of Health and Human ServicesInventors: Kimberly DOWD, Barney S. GRAHAM, Sung-Youl KO, Wing-Pui KONG, John MASCOLA, Theodore PIERSON, Mayuri SHARMA, Dong Yu
-
Publication number: 20190330279Abstract: Disclosed are recombinant insect ferritin nanoparticles that can be used to display two different trimeric antigens at an equal ratio. Also disclosed are nucleic acids encoding the recombinant insect ferritin nanoparticles and methods of producing the recombinant insect ferritin nanoparticles. Methods for eliciting an immune response in a subject are also provided.Type: ApplicationFiled: June 27, 2017Publication date: October 31, 2019Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServiceInventors: Peter Kwong, Ivelin Georgiev, Michael Gordon Joyce, Masaru Kanekiyo, Aliaksandr Druz, Ulrich Baxa, Joseph Van Galen, Rita Chen, Cheng Cheng, John Mascola, Yaroslav Tsybovsky, Yongping Yang, Paul Thomas, Barney Graham, Syed Mohammad Moin, Jeffrey Boyington, Kizzmekia Corbett
-
Patent number: 10400015Abstract: HIV-1 Env ectodomain trimers stabilized in a prefusion mature closed conformation and methods of their use and production are disclosed. In several embodiments, the HIV-1 Env ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject. In additional embodiments, the therapeutically effective amount of the HIV-1 Env ectodomain trimers can be administered to a subject in a method of treating or preventing HIV-1 infection.Type: GrantFiled: September 4, 2015Date of Patent: September 3, 2019Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Peter Kwong, Marie Pancera, Tongqing Zhou, Ivelin Georgiev, Michael Gordon Joyce, Priyamvada Acharya, Jason Gorman, Yongping Yang, Aliaksandr Druz, Guillaume Stewart-Jones, Rita Chen, Gwo-Yu Chuang, Ulrich Baxa, John Mascola, Rebecca Lynch, Baoshan Zhang, Cheng Cheng
-
Publication number: 20190256579Abstract: Methods of inducing an immune response in a subject to the Middle East respiratory syndrome coronavirus (MERS-CoV) are provided. In several embodiments, the immune response is a protective immune response that inhibits or prevents MERS-CoV infection in the subject. Recombinant MERS-CoV polypeptides and nucleic acid molecules encoding same are also provided. Additionally, neutralizing antibodies that specifically bind to MERS-CoV S protein and antigen binding fragments thereof are disclosed. The antibodies and antigen binding fragments are useful, for example, in methods of detecting MERS-CoV S protein in a sample or in a subject, as well as methods of preventing and treating a MERS-CoV infection in a subject.Type: ApplicationFiled: May 3, 2019Publication date: August 22, 2019Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Barney Graham, Wing-Pui Kong, Kayvon Modjarrad, Lingshu Wang, Wei Shi, Michael Gordon Joyce, Masaru Kanekiyo, John Mascola
-
Patent number: 10301377Abstract: Methods of inducing an immune response in a subject to the Middle East respiratory syndrome coronavirus (MERS-CoV) are provided. In several embodiments, the immune response is a protective immune response that inhibits or prevents MERS-CoV infection in the subject. Recombinant MERS-CoV polypeptides and nucleic acid molecules encoding same are also provided. Additionally, neutralizing antibodies that specifically bind to MERS-CoV S protein and antigen binding fragments thereof are disclosed. The antibodies and antigen binding fragments are useful, for example, in methods of detecting MERS-CoV S protein in a sample or in a subject, as well as methods of preventing and treating a MERS-CoV infection in a subject.Type: GrantFiled: February 24, 2016Date of Patent: May 28, 2019Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Barney Graham, Wing-Pui Kong, Kayvon Modjarrad, Lingshu Wang, Wei Shi, Michael Gordon Joyce, Masaru Kanekiyo, John Mascola
-
Publication number: 20190112340Abstract: Embodiments of a recombinant Respiratory Syncytial Virus (RSV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the RSV F ectodomain trimer and methods of producing the RSV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the recombinant RSV F ectodomain trimer to the subject.Type: ApplicationFiled: March 29, 2017Publication date: April 18, 2019Applicant: The United States of America, as represented by the Secretary, Department of Health and HumanInventors: Peter Kwong, Barney Graham, John Mascola, Li Ou, Aliaksandr Druz, Man Chen, Wing-Pui Kong, Ivelin Stefanov Georgiev, Emily Rundlet, Michael Gordon Joyce, Yaroslav Tsybovsky, Paul Thomas, Marie Pancera, Mallika Sastry, Cinque Soto, Joseph Van Galen, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Ulrich Baxa
-
Publication number: 20190077849Abstract: Neutralizing antibodies that specifically bind to HIV-1 Env and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.Type: ApplicationFiled: November 3, 2016Publication date: March 14, 2019Applicants: The Trustees of Columbia University in the City of New York, The United States of AMerica, as represented by the Secretary, Department of Health and Human SercInventors: Peter Kwong, Young Do Kwon, Ivelin Georgiev, Gilad Ofek, Baoshan Zhang, Krisha McKee, John Mascola, Mark Connors, Gwo-Yu Chuang, Sijy O'Dell, Robert Bailer, Mark Louder, Mangaiarkarasi Asokan, Richard Schwartz, Jonathan Cooper, Kevin Carlton, Michael Bender, Amarendra Pegu, Lawrence Shapiro, Tatyana Gindin, Lisa Kueltzo
-
Publication number: 20190016786Abstract: Monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV infection is disclosed.Type: ApplicationFiled: July 24, 2018Publication date: January 17, 2019Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Peter D. Kwong, Gary J. Nabel, Rebecca S. Rudicell, John Mascola, Mark Connors, Ivelin Georgiev, Jiang Zhu, Young Do Kwon, Tongqing Zhou, Yongping Yang, Baoshan Zhang, Gwo-Yu Chuang, Xueling Wu, Zhi-yong Yang, Wei Shi
-
Publication number: 20180298083Abstract: Antibodies and antigen binding fragments that specifically bind to gp120 and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.Type: ApplicationFiled: March 18, 2016Publication date: October 18, 2018Applicant: The United States of America, as repsented By the Secretary, Department of Health and Human ServicesInventors: Mark Connors, Jinghe Huang, Byong Ha Kang, John Mascola, Elise Ishida, Tongqing Zhou, Peter Kwong, Anqi Zheng
-
Publication number: 20180244756Abstract: Methods of inducing an immune response in a subject to the Middle East respiratory syndrome coronavirus (MERS-CoV) are provided. In several embodiments, the immune response is a protective immune response that inhibits or prevents MERS-CoV infection in the subject. Recombinant MERS-CoV polypeptides and nucleic acid molecules encoding same are also provided. Additionally, neutralizing antibodies that specifically bind to MERS-CoV S protein and antigen binding fragments thereof are disclosed. The antibodies and antigen binding fragments are useful, for example, in methods of detecting MERS-CoV S protein in a sample or in a subject, as well as methods of preventing and treating a MERS-CoV infection in a subject.Type: ApplicationFiled: February 24, 2016Publication date: August 30, 2018Applicant: The United States of America, as Represented by the Secretary, Dept. of Health and Human ServicesInventors: Barney Graham, Wing-Pui Kong, Kayvon Modjarrad, Lingshu Wang, Wei Shi, Michael Gordon Joyce, Masaru Kanekiyo, John Mascola
-
Patent number: 10047147Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection.Type: GrantFiled: August 4, 2014Date of Patent: August 14, 2018Assignee: The United States of American, as represented by the Secretary, Department of Health and Human ServicesInventors: Mark Connors, Jinghe Huang, Leo Laub, John Mascola, Nancy Longo, Nicole Doria-Rose
-
Patent number: 10035845Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and the use of these antibodies are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes.Type: GrantFiled: July 27, 2017Date of Patent: July 31, 2018Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of WashingtonInventors: John Mascola, Richard Wyatt, Xueling Wu, Yuxing Li, Carl-Magnus Hogerkorp, Mario Roederer, Zhi-yong Yang, Gary Nabel, Peter Kwong, Tongqing Zhou, Mark Connors, William Schief
-
Patent number: 10035844Abstract: Monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV infection is disclosed.Type: GrantFiled: June 2, 2017Date of Patent: July 31, 2018Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Peter D. Kwong, Gary J. Nabel, Rebecca S. Rudicell, John Mascola, Mark Connors, Ivelin Georgiev, Jiang Zhu, Young Do Kwon, Tongqing Zhou, Yongping Yang, Baoshan Zhang, Gwo-Yu Chuang, Xueling Wu, Zhi-yong Yang, Wei Shi
-
Patent number: 10004800Abstract: The present invention relates, in general, to HIV-1 and, in particular, to broadly neutralizing HIV-1 antibodies, and to HIV-1 immunogens and to methods of using such immunogens to induce the production of broadly neutralizing HIV-1 antibodies in a subject (e.g., a human).Type: GrantFiled: September 12, 2013Date of Patent: June 26, 2018Assignees: Duke University, Los Alamos National Security, LLC, The Trustees of The University of Pennsylvania, Trustees of Boston University, The United States of America as Represented by The Secretary of the Department of Health and Human Services National Institutes of Health Office of Technology Transfer, The Board of Trustees of the Leland Stanford Junior UniversityInventors: Barton F. Haynes, Hua-Xin Liao, Rebecca M. Lynch, Tongqing Zhou, Feng Gao, Scott Boyd, George M. Shaw, Beatrice H. Hahn, Thomas B. Kepler, Bette T. Korber, Peter Kwong, John Mascola
-
Publication number: 20170369558Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and the use of these antibodies are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes.Type: ApplicationFiled: July 27, 2017Publication date: December 28, 2017Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Serv, University of WashingtonInventors: John Mascola, Richard Wyatt, Xueling Wu, Yuxing Li, Carl-Magnus Hogerkorp, Mario Roederer, Zhi-yong Yang, Gary Nabel, Peter Kwong, Tongqing Zhou, Mark Connors, William Schief
-
Patent number: 9796774Abstract: The present application relates novel HIV-1 broadly neutralizing antibodies. The antibodies of the present invention are further characterized by their ability to bind epitopes from the Env proteins. The invention also provides light and heavy chain variable region sequences. Compositions for prophylaxis, diagnosis and treatment of HIV infection are provided.Type: GrantFiled: April 19, 2016Date of Patent: October 24, 2017Assignees: INTERNATIONAL AIDS VACCINE INITIATIVE, THE SCRIPPS RESEARCH INSTITUTEInventors: John Mascola, Dennis R. Burton, Wayne Koff, Peter Kwong, Gary Nabel, Sanjay K. Phogat, Pascal Raymond Georges Poignard, Melissa Danielle De Jean St. Marcel Simek-Lemos, Xueling Wu, Tongqing Zhou, Zhi-Yong Yang